🇪🇺 Macugen in European Union

EMA authorised Macugen on 31 January 2006

Marketing authorisation

EMA — authorised 31 January 2006

  • Application: EMEA/H/C/000620
  • Marketing authorisation holder: PharmaSwiss Ceska Republika s.r.o
  • Local brand name: Macugen
  • Indication: Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
  • Status: withdrawn

Read official source →

Macugen in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Ophthalmology approved in European Union

Frequently asked questions

Is Macugen approved in European Union?

Yes. EMA authorised it on 31 January 2006.

Who is the marketing authorisation holder for Macugen in European Union?

PharmaSwiss Ceska Republika s.r.o holds the EU marketing authorisation.